Company Overview of Epizyme, Inc.
Epizyme, Inc., a clinical stage biopharmaceutical company, discovers and develops personalized therapeutics for patients with genetically defined cancers. It identifies the genetic alterations that create cancer causing genes, known as oncogenes; selects patients in whom the identified genetic alteration is found; and designs small molecule therapeutic product candidates to inhibit the oncogene. The company has two histone methyltransferases (HMT) inhibitors in clinical development for the treatment of patients with genetically defined cancers. It is conducting a Phase I clinical trial of its product candidate, EPZ-5676, an inhibitor targeting the DOT1L HMT for the treatment of acute leukemi...
400 Technology Square
Cambridge, MA 02139
Founded in 2007
Key Executives for Epizyme, Inc.
Chief Executive Officer
Total Annual Compensation: $564.7K
Total Annual Compensation: $513.2K
Chief Scientific Officer and Executive Vice President
Total Annual Compensation: $487.5K
Chief Medical Officer
Total Annual Compensation: $463.5K
Compensation as of Fiscal Year 2013.
Epizyme, Inc. Key Developments
Epizyme, Inc. Reports Unaudited Consolidated Earnings Results for the Second Quarter and Six Months Ended June 30, 2014; Provides Earnings Guidance for the Full Year of 2014
Aug 13 14
Epizyme, Inc. reported unaudited consolidated earnings results for the second quarter and six months ended June 30, 2014. For the quarter, the company reported collaboration revenue of $9,494,000 against $14,839,000 a year ago. Loss from operations was $13,311,000 against $2,177,000 a year ago. Loss allocable to common stockholders was $13,386,000 or $0.40 per basic and diluted share against $2,319,000 or $0.25 per basic and diluted share a year ago.
For the six months, the company reported collaboration revenue of $22,885,000 against $23,721,000 a year ago. Loss from operations was $20,223,000 against $9,654,000 a year ago. Loss allocable to common stockholders was $20,270,000 or $0.63 per basic and diluted share against $9,973,000 or $1.82 per basic and diluted share a year ago.
The company provided cash flow guidance for the full year 2014. The company continues to expect full-year 2014 net cash used in operating activities to be approximately $50 million, including $34 million in accounts receivable recorded in 2013 but collected in 2014. Excluding these accounts receivable, adjusted net cash used in operating activities in 2014 is expected to be approximately $80 million. The company expects to end 2014 with more than $170 million in cash and cash equivalents, which is expected to fund the company until at least mid-2016, prior to including any potential future milestone payments.
Epizyme Announces Pre-Clinical Data and Early Clinical Observations from Ongoing Phase 1 Trial of EZH2 Inhibitor EPZ-6438 (E7438) at ASH Meeting on Lymphoma Biology
Aug 12 14
Epizyme, Inc. reported pre-clinical data and early clinical observations from an ongoing Phase 1 trial, being conducted in collaboration with Eisai, the Institut Gustave Roussy, and the Institut Bergonie, of EZH2 inhibitor EPZ-6438 (E7438) in patients with advanced solid tumors and B-cell lymphomas. These data were presented by Robert Copeland, Ph.D., Chief Scientific Officer, Epizyme, during an oral session on novel therapeutics in lymphoma at the American Society of Hematology (ASH) meeting on Lymphoma Biology, held August 10-13 in Colorado Springs, Colorado. Pre-clinical data have shown the utility of single-agent EZH2 inhibitors in both EZH2 mutant and EZH2 wild type germinal center (GC) NHL models. Data presented showed that in pre-clinical studies in GC NHL cell lines, combining EPZ-6438 with CHOP, a chemotherapy cocktail regimen that is a standard of care in NHL, resulted in strong synergy of lymphoma cell killing. When EPZ-6438 was combined with each individual component of the CHOP regimen, the synergy was great with prednisone, the corticosteroid component of CHOP. Prednisone greatly enhanced the potency of EPZ-6438 for killing EZH2 mutant-bearing lymphoma cell lines, and broadened the activity of EPZ-6438 to all GC NHL cell lines, regardless of EZH2 mutational status. Combining EPZ-6438 with dexamethasone, another corticosteroid, yielded similar synergistic results. Synergy was also observed in both EZH2 mutant and wild type cell lines when EPZ-6438 was combined with B-cell signaling pathway agents and BCL2 antagonists. The primary objective of the ongoing Phase 1 dose escalation study is to evaluate the safety and tolerability of EPZ-6438 and determine the maximum tolerated dose (MTD) or recommended Phase 2 dose (RP2D); the secondary objectives are to determine pharmacokinetics (PK) and pharmacodynamics (PD) of EPZ-6438. The study to date consists of five dosing cohorts, with evaluation of doses of 100 mg to 1600 mg BID, orally administered in 28-day cycles without a drug holiday in patients with advanced solid tumors or with relapsed or refractory B-cell lymphoma. Three of five dosing cohorts (100, 200 and 400 mg) have been completed with 12 evaluable patients dosed, four of whom were NHL patients. Dose cohorts evaluating 800 mg and 1600 mg are ongoing. Early clinical observations from the three completed cohorts include: MTD has not been reached; there were no DLTs or AE-related treatment discontinuations. PK was dose-proportional across these three cohorts. PD evidence of target inhibition was observed in skin. Two NHL patients achieved objective responses: a partial response in a patient with relapsed transformed diffuse large B-cell lymphoma (DLBCL), and an ongoing partial response in a patient with primary refractory mediastinal B-cell lymphoma (PMBCL). Additionally, a patient with follicular lymphoma with EZH2 mutation had stable disease.
Epizyme, Inc. to Report Q2, 2014 Results on Aug 13, 2014
Jul 28 14
Epizyme, Inc. announced that they will report Q2, 2014 results on Aug 13, 2014
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|